{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["54(5)"],"submitter":["Nagahara A"],"funding":["Astellas Pharma Inc."],"pubmed_abstract":["<h4>Background</h4>Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide.<h4>Methods</h4>The DELC study enrolled 163 Japanese patients with castration-resistant prostat"],"journal":["Japanese journal of clinical oncology"],"pagination":["584-591"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11075733"],"repository":["biostudies-literature"],"pubmed_title":["Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study."],"pmcid":["PMC11075733"],"pubmed_authors":["Nonomura N","Nishimura K","Takao T","Okada K","Takada S","Iwanishi T","Matsumura S","Uemura M","Inoue H","Fujita K","Kato T","Takada T","Ujike T","Nakata W","Tsujihata M","Ishizuya Y","Kobayashi Y","Sato M","Kawashima A","Nagahara A","Hatano K"],"additional_accession":[]},"is_claimable":false,"name":"Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.","description":"<h4>Background</h4>Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide.<h4>Methods</h4>The DELC study enrolled 163 Japanese patients with castration-resistant prostat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-04-08T19:39:41.697Z","creation":"2026-04-08T14:12:14.84Z"},"accession":"S-EPMC11075733","cross_references":{"pubmed":["38305451"],"doi":["10.1093/jjco/hyae004"]}}